Randomized phase III trial evaluating the role of weight loss in adjuvant treatment of overweight and obese women with early breast cancer (Alliance A011401): study design

npj Breast Cancer

Volumn 3, Issue 1, 2017, Pages

  Ligibel, Jennifer A ^a   Barry, William T ^a   Alfano, Catherine ^b   Hershman, Dawn L ^c   Irwin, Melinda ^d   Neuhouser, Marian ^e   Thomson, Cynthia A ^f   Delahanty, Linda ^g   Frank, Elizabeth ^a   Spears, Patty ^h   Paskett, Electra D ⁱ   Hopkins, Judith ^j   Bernstein, Vanessa ^k   Stearns, Vered ^l   White, Julia ⁱ   Hahn, Olwen ^m   Hudis, Clifford ⁿ   Winer, Eric P ^a   Wadden, Thomas A ^o   Goodwin, Pamela J ^p  

^a DANA FARBER CANCER INSTITUTE   (United States)

^b AMERICAN CANCER SOCIETY   (United States)

^c Department of Medicine   (United States)

^d YALE UNIVERSITY   (United States)

^e USA   (United States)

^f UNIVERSITY OF ARIZONA   (United States)

^g MASSACHUSETTS GENERAL HOSPITAL CANCER CENTER   (United States)

^h NORTH CAROLINA STATE UNIVERSITY   (United States)

ⁱ THE OHIO STATE UNIVERSITY WEXNER MEDICAL CENTER   (United States)

^j Novant Health Oncology Specialists Winston Salem   (United States)

^k UNIVERSITY OF BRITISH COLUMBIA   (Canada)

^l JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE   (United States)

^m UNIVERSITY OF CHICAGO   (United States)

ⁿ AMERICAN SOCIETY OF CLINICAL ONCOLOGY   (United States)

^o UNIVERSITY OF PENNSYLVANIA   (United States)

^p UNIVERSITY OF TORONTO   (Canada)

more..

Author keywords

[No Author keywords available]

Indexed keywords

EID: 85044213382     PISSN: None     EISSN: 23744677     Source Type: Journal    
DOI: 10.1038/S41523-017-0040-8     Document Type: Review

References (23)

1. Chan, D. S. et al. Body mass index and survival in women with breast cancersystematic literature review and meta-analysis of 82 follow-up studies. Ann. Oncol. 25, 1901–1914 (2014).
2. Protani, M., Coory, M. & Martin, J. H. Effect of obesity on survival of women with breast cancer: systematic review and meta-analysis. Breast Cancer Res. Treat. 123, 627–635 (2010).
3. Chlebowski, R., Aiello, E. & McTiernan, A. Weight loss in breast cancer patient management. J. Clin. Oncol. 20, 1128–1143 (2002).
4. Chlebowski, R. et al. Mature analysis from the womens intervention nutrition study (WINS) evaluating dietary fat reduction and breast cancer outcome. Breast Cancer Res. Treat. 100, S16 abstr (2006).
5. Pierce, J. et al. Influence of a diet very high in vegetables, fruit, and fiber and low in fat on prognosis following treatment for breast cancer: the Women's Healthy Eating and Living (WHEL) randomized trial. JAMA 298, 289–298 (2007).
6. Goodwin, P. et al. Fasting Insulin and outcome in early-stage breast cancer: results of a prospective cohort study. J. Clin. Oncol. 20, 42–51 (2002).
7. Duggan, C. et al. Associations of insulin resistance and adiponectin with mortality in women with breast cancer. J. Clin. Oncol. 29, 32–39 (2011).
8. Irwin, M. L. et al. Fasting C-peptide levels and death resulting from all causes and breast cancer: the health, eating, activity, and lifestyle study. J. Clin. Oncol. 29, 47–53 (2011).
9. Pollak, M. et al. Insulin resistance, estimated by serum C-peptide level, is associated with reduced event-free survival for postmenopausal women in NCIC CTG MA.14 adjuvant breast cancer trial. J. Clin. Oncol. 24, 524 abstr (2006).
10. Hanksinson, S. et al. Circulating concentrations of insulin-like growth factor-1 and risk of breast cancer. Lancet 351, 1393–1396 (1998).
11. Rose, D., Gilhooly, E. & Nixon, D. Adverse effects of obesity on breast cancer prognosis, and the biological actions of leptin. Int. J. Oncol. 21, 1285–1292 (2002).
12. Rose, D., Komninou, D. & Stephenson, G. D. Obseity, adipocytokines, and insulin resistance in breast cancer. Obes. Rev. 5, 153–165 (2004).
13. Chen, D. et al. Serum adiponectin and leptin levels in Taiwanese breast cancer patients. Cancer Lett. 237, 109–114 (2006).
14. Mantzoros, C. et al. Adiponectin and breast cancer risk. J. Clin. Endocrinol. Metab. 89, 1102–1107 (2004).
15. Handschin, C. & Spiegelman, B. The role of exercise and PGC1α in inflammation and chronic disease. Nature 454, 463–469 (2008).
16. Morris, P. G. et al. Inflammation and increased aromatase expression occur in the breast tissue of obese women with breast cancer. Cancer Prev. Res.(Phila) 4, 1021–1029 (2011).
17. Lin, W. & Karin, M. A cytokine-mediated link between innate immunity,inflammation, and cancer. J. Clin. Invest. 117, 1175–1183 (2007).
18. Hudis, C. A. et al. Proposal for standardized definitions for efficacy end points in adjuvant breast cancer trials: the STEEP system. J. Clin. Oncol. 25, 2127–2132 (2007).
19. Knowler, W. C. et al. Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin. N. Engl. J. Med. 346, 393–403 (2002).
20. Wadden, T. A. et al. Four-year weight losses in the Look AHEAD study: factors associated with long-term success. Obesity 19, 1987–1998 (2011).
21. Goodwin, P. J. et al. Randomized trial of a telephone-based weight loss intervention in postmenopausal women with breast cancer receiving letrozole: the LISA trial. J. Clin. Oncol. 32, 2231–2239 (2014).
22. Cox, D. R. Regression models and life-tables. J. R. Stat. Soc. Series B Methodol. 34, 187–220 (1972).
23. Miller, K. et al. Bevacizumab (Bv) in the adjuvant treatment of HER2-negative breast cancer: final results from eastern cooperative oncology group E5103. J. Clin. Oncol. 32, abstr 500 (2014).